Intech Investment Management LLC Purchases New Holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Intech Investment Management LLC purchased a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 25,814 shares of the company's stock, valued at approximately $927,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC raised its stake in shares of Dyne Therapeutics by 904.1% in the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company's stock valued at $26,000 after acquiring an additional 669 shares during the period. US Bancorp DE increased its stake in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company's stock worth $49,000 after buying an additional 1,212 shares during the period. Values First Advisors Inc. purchased a new position in Dyne Therapeutics in the 3rd quarter valued at about $62,000. KBC Group NV grew its stake in shares of Dyne Therapeutics by 53.4% during the third quarter. KBC Group NV now owns 2,157 shares of the company's stock valued at $77,000 after acquiring an additional 751 shares in the last quarter. Finally, Amalgamated Bank lifted its stake in shares of Dyne Therapeutics by 39.9% in the second quarter. Amalgamated Bank now owns 2,792 shares of the company's stock worth $99,000 after acquiring an additional 796 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company's stock.

Dyne Therapeutics Stock Performance

Shares of NASDAQ:DYN traded down $0.52 during trading hours on Friday, hitting $30.61. The stock had a trading volume of 469,452 shares, compared to its average volume of 1,475,934. Dyne Therapeutics, Inc. has a 1-year low of $10.33 and a 1-year high of $47.45. The stock's fifty day simple moving average is $31.78 and its 200 day simple moving average is $35.36. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of -8.74 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by ($0.25). As a group, research analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Analyst Upgrades and Downgrades

DYN has been the topic of several analyst reports. HC Wainwright restated a "buy" rating and set a $55.00 price objective on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Stifel Nicolaus increased their price objective on shares of Dyne Therapeutics from $41.00 to $66.00 and gave the company a "buy" rating in a research note on Friday, August 16th. Royal Bank of Canada started coverage on shares of Dyne Therapeutics in a research report on Tuesday. They issued an "outperform" rating and a $45.00 target price for the company. Piper Sandler reiterated an "overweight" rating and issued a $53.00 price target on shares of Dyne Therapeutics in a research note on Monday, September 23rd. Finally, JPMorgan Chase & Co. cut Dyne Therapeutics from an "overweight" rating to a "neutral" rating and cut their price objective for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $50.82.

Insiders Place Their Bets

In other Dyne Therapeutics news, COO Susanna Gatti High sold 8,976 shares of the company's stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.41, for a total value of $308,864.16. Following the completion of the sale, the chief operating officer now directly owns 131,636 shares of the company's stock, valued at approximately $4,529,594.76. This represents a 6.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Carlo Incerti sold 16,500 shares of Dyne Therapeutics stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total transaction of $474,045.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 176,257 shares of company stock worth $6,193,718. 20.77% of the stock is owned by corporate insiders.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.